CareDx

CareDx announces DOJ concluded investigation with no finding of wrongdoing, declining to prosecute. This follows SEC's decision in 2023 to close its investigation without action. CareDx will defend itself if former employee proceeds with litigation.

Technology enhances diversity in diabetes clinical trials by expanding outreach, simplifying participation, and improving data collection, leading to more inclusive and effective research outcomes.

CareDx awarded 14 new employees 44,000 restricted stock units (RSUs) on Sept 12, 2024, under its 2019 Inducement Equity Incentive Plan. The RSUs vest over periods ranging from two to four years, subject to continued service.

CareDx granted Keith S. Kennedy and Jessica Meng, its new COO and CCO, inducement options and RSUs on Sept 12, 2024, approved by the Compensation and Human Capital Committee, in accordance with Nasdaq Listing Rule 5635(c)(4).